rAd-Grim-19

**rAd-Grim-19** is an experimental **gene therapy** consisting of a recombinant adenoviral vector engineered to express **GRIM-19** (gene associated with retinoid-interferon-induced mortality 19), a tumor-suppressive and pro-apoptotic protein. In the provided preclinical esophageal cancer study, the agent was evaluated in **esophageal squamous cell carcinoma** models, where GRIM-19 expression was reduced in tumor cells and adenoviral restoration of GRIM-19 increased apoptosis, inhibited tumor-cell proliferation, and prolonged survival in tumor-bearing mice. The therapeutic concept is antineoplastic gene replacement or forced re-expression of GRIM-19 to suppress malignant growth, likely through restoration of GRIM-19-mediated apoptotic and growth-inhibitory signaling. No marketed name, manufacturer, or clearly identified commercial developer is established from the provided context.

Other names

recombinant adenovirus expressing Grim-19